1David L, Dewitt D, Elizabeth A, et al. PGH synthase iscenzyme selectivity: the potential for safer nonsteroidal anti- inflammatory drugs [J]. Am J Med, 1993, 95(Supp12A): 40-44s.
2Crofford L. COX- 1 and COX- 2 tissue expression: implications and predictions [J]. J Rheumatol, 1997, 24(Suppl 49) : 15 -19.
3Honkanen V, Lahdenne P. Risks and benefits of nonsteroidal anti- inflammatory drugs in children: a comparison with paracetamol[J]. Paediatr Drugs, 2001, 3(11): 817-858.
4De Silva B, Banney L, Uttley W, et al. Pseudoporphyria and nonsteroidal anti - inflammatory agents in children with juvenile idiopathic arthritis [J]. Pediatr Dermatol, 2001, 17(6) : 480 -483.
5Ailioaie C, Lupusoru - Ailioaie LM. Antirheumatic effects of first-line agents in the treatment of juvenile chronic arthritis [J].Rev Med Chir Soc Med Nat Iasi, 1997, 101(3-4): 134- 138.
6Prineipi N. Guidelines for the therapeutic use of NSAIDS in pediattics [J]. Minerva Pediatr, 1997, 49(9) : 379 - 386.
7Randy Q, Cron D, Seerna S, et al. Cttrrent treatment by united states and Canadian pediatric rheumatologists [J ]. J Rheumatol,1999, 26(8) : 2036 - 2038.
8Girschick HJ, Seyberth HW, Huppertz HI. Treatment of childhood hypophosphatasia with nonsteroidal anti- inflammatory drugs [J]. Bone, 1999, 25(5): 603-607.
9Joseph D, Tobias MD. Weak anglgesics and nonsteroidal anti-inflammatory agents in the management of children with acutepain [J]. Pediatr Clin North Am, 2000, 47(3): 527-543.
